Difference between revisions of "Baker Pharmaceuticals"
Sarna News
CungrVanck (talk | contribs) |
m (clean-up/update) |
||
| Line 1: | Line 1: | ||
| − | + | '''Baker Pharmaceuticals''' was a pharmaceutical company in the [[Lyran Commonwealth]], with its assets eventually acquired by the mammoth [[Nashan Diversified]]. <ref name=HSTLC-144>''House Steiner (The Lyran Commonwealth)'', p. 144 "Socioeconomics - Other Major Commonwealth Industries - Baker Pharmaceuticals"</ref> <ref name=HHS-134>''Handbook: House Steiner'', p. 134 - "Economics - Major Industries- Nashan Diversified".</ref> | |
| − | |||
| − | '''Baker Pharmaceuticals''' | ||
==Company Profile== | ==Company Profile== | ||
| − | '''Commonwealth Stock Exchange Symbol:''' BakPhar | + | '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-144/> |
| − | '''Home Office:''' New Benner, [[Baker 3]] | + | '''Home Office:''' New Benner, [[Baker 3]] (circa [[3024]]).<ref name=HSTLC-144/> |
| − | '''President/CEO:''' John Sleeth | + | '''President/CEO:''' John Sleeth (circa 3024).<ref name=HSTLC-144/> |
==Overview== | ==Overview== | ||
| + | Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million [[Kroner|S-Bill]] lawsuit in [[3023]] when a batch of their synthetic molecular antibodies went toxic, killing over 100 [[Lyran Commonwealth Armed Forces]] soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in [[3024]], which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.<ref name=HSTLC-144/> | ||
| − | + | While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond [[3025]].<ref name=HSTLC-144/> Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer [[Donegal]] offices to serve as its '''Nashan Pharmaceuticals''' division.<ref name=HHS-134/> | |
==References== | ==References== | ||
| Line 19: | Line 18: | ||
==Bibliography== | ==Bibliography== | ||
| + | *''[[Handbook: House Steiner]]'' | ||
*''[[House Steiner (The Lyran Commonwealth)]]'' | *''[[House Steiner (The Lyran Commonwealth)]]'' | ||
[[Category:Companies]] | [[Category:Companies]] | ||
[[Category:Lyran Commonwealth Companies]] | [[Category:Lyran Commonwealth Companies]] | ||
Revision as of 21:47, 11 January 2015
Baker Pharmaceuticals was a pharmaceutical company in the Lyran Commonwealth, with its assets eventually acquired by the mammoth Nashan Diversified. [1] [2]
Company Profile
Commonwealth Stock Exchange Symbol: BakPhar. [1]
Home Office: New Benner, Baker 3 (circa 3024).[1]
President/CEO: John Sleeth (circa 3024).[1]
Overview
Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million S-Bill lawsuit in 3023 when a batch of their synthetic molecular antibodies went toxic, killing over 100 Lyran Commonwealth Armed Forces soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in 3024, which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.[1]
While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond 3025.[1] Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer Donegal offices to serve as its Nashan Pharmaceuticals division.[2]